Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Co-administered Shingrix or Flu D-QIV with mRNA-1273 Booster
NCT05047770Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2021
- Primary completion
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of herpes zoster vaccine (recombinant, adjuvanted), Fluarix Quadrivalent in herpes zoster (HZ), influenza, sponsored by GSK. Started Oct 2021; status: completed.
02
Drugs
herpes zoster vaccine (recombinant, adjuvanted)Fluarix Quadrivalent
03
Conditions
herpes zoster (HZ)influenza
Beyond the preview
Go deeper on NCT05047770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047770.